Sargent Investment Group LLC Boosts Stake in Novavax, Inc. (NASDAQ:NVAX)

Sargent Investment Group LLC raised its position in Novavax, Inc. (NASDAQ:NVAX) by 24.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 50,775 shares of the biopharmaceutical company’s stock after purchasing an additional 9,940 shares during the period. Sargent Investment Group LLC’s holdings in Novavax were worth $437,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NVAX. The Manufacturers Life Insurance Company increased its stake in shares of Novavax by 53.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 59,656 shares of the biopharmaceutical company’s stock worth $755,000 after purchasing an additional 20,709 shares during the last quarter. Algert Global LLC purchased a new stake in shares of Novavax during the 2nd quarter worth approximately $161,000. Creative Planning increased its stake in shares of Novavax by 12.5% during the 2nd quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 2,692 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of Novavax by 110.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock worth $6,296,000 after purchasing an additional 261,464 shares during the last quarter. Finally, OmniStar Financial Group Inc. purchased a new stake in shares of Novavax during the 3rd quarter worth approximately $163,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Insider Buying and Selling at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares of the company’s stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,150 shares of company stock valued at $119,641 in the last three months. Company insiders own 1.00% of the company’s stock.

Novavax Trading Up 1.9 %

Novavax stock opened at $8.60 on Thursday. Novavax, Inc. has a 1-year low of $3.60 and a 1-year high of $23.86. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -3.81, a P/E/G ratio of 66.26 and a beta of 2.14. The firm has a 50 day simple moving average of $8.80 and a 200 day simple moving average of $10.61.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same period in the previous year, the business earned ($1.26) earnings per share. The firm’s revenue for the quarter was down 54.8% on a year-over-year basis. On average, equities research analysts forecast that Novavax, Inc. will post -1.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NVAX shares. HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. B. Riley reiterated a “buy” rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Finally, Jefferies Financial Group reduced their price objective on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.